The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Open accessAbstract
BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS: We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures. RESULTS: As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. CONCLUSIONS: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Denosumab reduces the incidence of vertebral fractures by about 68 %, hip fractures by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
Johnell, O., & Kanis, J. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0172-4 · Cited by 4,770
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationEpidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Wells G, 2008, Cochrane Database Syst Rev, 1, CD004523
- Martin TJ, 2004, J Musculoskelet Neuronal Interact, 4, 243
Cited by
Sorted by citations
Items 901–1,000 of 1,006
Lee, C. E., Leslie, W. D., Czaykowski, P. M., Gingerich, J., Geirnaert, M., & Lau, Y.-K. (2011) · Current Oncology · doi:10.3747/co.v18i4.746 · Cited by 35
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Wensel, T. M., Iranikhah, M., & Wilborn, T. W. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.510 · Cited by 36
Functional and analytical recapitulation of osteoclast biology on demineralized bone paper
Park, Y., Sato, T., & Lee, J. (2023) · Nature Communications · doi:10.1038/s41467-023-44000-9 · Cited by 33
Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 42
Edwards, W. B., Simonian, N., Troy, K. L., & Schnitzer, T. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2474 · Cited by 37
Pharmacological diversity among drugs that inhibit bone resorption
Russell, R. G. G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.005 · Cited by 36
Denosumab: recent update in postmenopausal osteoporosis.
da Silva, I. S., & Branco, J. (2012) · PubMed · Cited by 33
Silverman, S. L., Agodoa, I., Kruse, M., Parthan, A., & ORWOLL, E. S. (2015) · Journal of Osteoporosis · doi:10.1155/2015/627631 · Cited by 34
Denosumab for the treatment of osteoporosis
McClung, M. R. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.01.002 · Cited by 36
Self-citationSite specific measurements of bone formation using [18F] sodium fluoride PET/CT
Blake, G. M., Puri, T., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2018) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2018.01.02 · Cited by 35
Inducible Wnt16 inactivation: WNT16 regulates cortical bone thickness in adult mice
Ohlsson, C., Henning, P., Nilsson, K. H., Wu, J., Gustafsson, K. L., Sjögren, K., Törnqvist, A. E., Koskela, A., Zhang, F., Lagerquist, M. K., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0020 · Cited by 34
Silverman, S. L., Siris, E. S., Belazi, D., Recknor, C. P., Παπαϊωάννου, Α., Brown, J. P., Gold, D. T., Lewiecki, E. M., Quinn, G., Balasubramanian, A., et al. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0491-z · Cited by 34
Self-citationKang, M.-H., Lee, D.-K., Kim, C.-W., Song, I., & Jun, S.-H. (2018) · 대한구강악안면외과학회지 · doi:10.5125/jkaoms.2018.44.5.225 · Cited by 34
Lamy, O., Fernández-Fernández, E., Monjo, I., Stoll, D., Aubry‐Rozier, B., Benavent-Núñez, D., Aguado, P., & Rodríguez, E. G. (2019) · Osteoporosis International · doi:10.1007/s00198-018-04820-8 · Cited by 34
Atypical femur fractures: current understanding and approach to management
Tile, L., & Cheung, A. M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20916983 · Cited by 34
Bone Mineral Disease After Kidney Transplantation
Torregrosa, J., Ferreira, A. C., Cucchiari, D., & Ferreira, A. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00837-0 · Cited by 39
Alessandro de, S. I. R. E., Lippi, L., Venetis, K., Morganti, S., Sajjadi, E., Curci, C., Ammendolia, A., Criscitiello, C., Fusco, N., & Invernizzi, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.829875 · Cited by 34
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
McGrath, E. E. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318229421f · Cited by 35
Advances in Osteoimmunology: Pathophysiologic Concepts and Treatment Opportunities
Rauner, M., Sipos, W., Thiele, S., & Pietschmann, P. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000342426 · Cited by 34
McClung, M. R., Zanchetta, J., Høiseth, A. D., Kendler, D. L., Yuen, C. K., Brown, J. P., Stonkus, S., Goemaere, S., Recknor, C. P., Woodson, G. C., et al. (2012) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2012.02.014 · Cited by 35
Self-citationTankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2
Mukai, T., Fujita, S., & Morita, Y. (2019) · Cells · doi:10.3390/cells8020195 · Cited by 34
Siu, A. L., Allore, H. G., Brown, D., Charles, S. T., & Lohman, M. C. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0961 · Cited by 34
Kobayashi, T., Morimoto, T., Ito, K., Mawatari, M., & Shimazaki, T. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07118-0 · Cited by 33
Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach
Lamy, O., Everts‐Graber, J., & Rodríguez, E. G. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-02991-z · Cited by 36
Safety concerns with the long-term management of osteoporosis
Reginster, J., Pelousse, F., & Bruyère, O. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793669 · Cited by 33
McGowan, B., Casey, M. C., Silke, C., Whelan, B., & Bennett, K. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2032-8 · Cited by 33
Cardiovascular disease and bone
Eastell, R., Newman, C., & Crossman, D. C. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.008 · Cited by 33
Self-citationPreventing osteoporosis in symptomatic postmenopausal women
Gallagher, J. C., & Levine, J. P. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181e324a6 · Cited by 33
Anastasilakis, A. D., Pοlyzos, S. A., Efstathiadou, Z. A., Savvidis, M. S., Sakellariou, G. T., Παπαθεοδώρου, Α., Kokkoris, P., & Makras, P. (2015) · Metabolism · doi:10.1016/j.metabol.2015.06.018 · Cited by 33
Li, M., Wang, W., Geng, L., Qin, Y., Dong, W., Zhang, X., Qin, A., & Zhang, M. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2330 · Cited by 33
Hambli, R., Boughattas, M. H., Daniel, J. L., & Kourta, A. (2016) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2016.03.010 · Cited by 36
Jacobsen, C., Metzler, P., Obwegeser, J. A., Zemann, W., & Grätz, K. W. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13605 · Cited by 33
Abdallah, B. M., & Ali, E. M. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0544-7 · Cited by 33
Howe, J. G., Hill, R. S., Stroncek, J. D., Shaul, J. L., Favell, D., Cheng, R., Engelke, K., Genant, H. K., Lee, D. C., Keaveny, T. M., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05230-0 · Cited by 34
Invernizzi, M., Alessandro de, S. I. R. E., Renò, F., Cisari, C., Runza, L., Baricich, A., Carda, S., & Fusco, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00204 · Cited by 34
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis
Prather, C., Adams, E. N., & Zentgraf, W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa285 · Cited by 35
Qiang, G., Zhang, C., Wang, J., Wei, Q., Wei, Q., Miyamoto, A., Zhu, S., & He, C. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0705-z · Cited by 33
Querrer, R., Ferrare, N., de Melo, N. S., Stefani, C. M., dos Reis, P. E. D., Mesquita, C. R. M., Borges, G. Á., Leite, A. F., & Figueiredo, P. T. D. S. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05855-6 · Cited by 33
Muraca, M., & Cappariello, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228682 · Cited by 35
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 35
Gupta, A., & MARCH, L. M. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.028 · Cited by 35
Role of osteoclasts in regulating hematopoietic stem and progenitor cells
Miyamoto, T. K. (2013) · World Journal of Orthopedics · doi:10.5312/wjo.v4.i4.198 · Cited by 37
Orthopedic surgery and its complication in systemic lupus erythematosus
Mak, A. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i1.38 · Cited by 33
A nonsynonymous TNFRSF11A variation increases NFκB activity and the severity of Paget's disease
Gianfrancesco, F., Rendina, D., Stefano, M. D., Mingione, A., Esposito, T., Merlotti, D., Gallone, S., Magliocca, S., Goode, A., Formicola, D., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.542 · Cited by 33
The RANKL Pathway and Denosumab
Dore, R. K. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.07.004 · Cited by 33
Henriksen, K., Leeming, D. J., Christiansen, C., & Karsdal, M. A. (2011) · Women s Health · doi:10.2217/whe.11.74 · Cited by 32
Self-citationLeder, B. Z., Tsai, J. N., Neer, R. M., Uihlein, A. V., Wallace, P. M., & Burnett‐Bowie, S. M. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.01.004 · Cited by 33
Otto, S., Burian, E., Troeltzsch, M., Kaeppler, G., & Ehrenfeld, M. (2017) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2017.10.011 · Cited by 33
Georgakopoulou, E. A., Stebbing, J., & Scully, C. M. (2018) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2017.08.046 · Cited by 33
Unexpected Bone Formation Produced by RANKL Blockade
Portal-Núñez, S., Mediero, A., Esbrit, P., Sánchez-Pernaute, O., Largo, R., & Herrero-Beaumont, G. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.06.003 · Cited by 32
Sølling, A. S., Harsløf, T., Jørgensen, N. R., & Langdahl, B. L. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06651-0 · Cited by 33
Paccou, J., Brazier, M., Mentaverri, R., Kamel, S., Fardellone, P., & Massy, Z. A. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.008 · Cited by 32
Management of bone metastases in refractory prostate cancer – role of denosumab
Paller, C. J., Philips, & Carducci, M. A. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s27930 · Cited by 34
Differential Response of MC3T3-E1 and Human Mesenchymal Stem Cells to Inositol Hexakisphosphate
Arriero, M. D. M., Ramis, J. M., Perelló, J., & Monjo, M. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000341474 · Cited by 33
Osteoporosis treatment: Focus on safety
Reid, I. R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.03.012 · Cited by 32
Self-citationRandomized trials are frequently fragmented in multiple secondary publications
Ebrahim, S., Montoya, L., el Din, M. K., Sohani, Z. N., Agarwal, A., Bance, S., Saquib, J., Saquib, N., & Ioannidis, J. P. A. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.05.016 · Cited by 34
Sawamura, M., Komatsuda, A., Togashi, M., Wakui, H., & Takahashi, N. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7797 · Cited by 32
The Epidemiology and Pathogenesis of Osteoporosis
Rosen, C. J. (2014) · Europe PMC (PubMed Central) · Cited by 32
Long-term treatment strategies for postmenopausal osteoporosis
Cosman, F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000509 · Cited by 33
Emerging anti-osteoclast therapy for rheumatoid arthritis
Tanaka, S. (2018) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2018.06.001 · Cited by 32
Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease
Jalleh, R. J., Basu, G., Leu, R. K. L., & Jesudason, S. (2018) · Case Reports in Nephrology · doi:10.1155/2018/7384763 · Cited by 32
Laboratory aspects and clinical utility of bone turnover markers.
Bhattoa, H. P. (2018) · Europe PMC (PubMed Central) · Cited by 32
Behanová, M., Reichardt, B., Stamm, T., Zwerina, J., Klaus Klaushofer, A., & Kocijan, R. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00611-3 · Cited by 33
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Kim, B., Lee, S. H., & Koh, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.55 · Cited by 34
Kim, H. Y. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1170 · Cited by 34
Riancho, J. A., Peris, P., González-Macı́as, J., & Pérez‐Castrillón, J. L. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2021.12.007 · Cited by 31
Schmiedel, B. J., Nuebling, T., Steinbacher, J., Malinovska, A., Wende, C. M., Azuma, M., Schneider, P., Große‐Hovest, L., & Salih, H. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201792 · Cited by 32
The Risks and Benefits of Calcium Supplementation
Shin, C. S., & Kim, K. M. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.27 · Cited by 33
Emerging Targets in Osteoporosis Disease Modification
Allen, J. G., Fotsch, C. H., & Babij, P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9018756 · Cited by 32
Olsen, K. R., Hansen, C. A., & Abrahamsen, B. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2365-y · Cited by 32
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2011) · Bone · doi:10.1016/j.bone.2011.05.031 · Cited by 32
Osteoporosis: Therapeutic Options
Ivanova, S. A., Mihaylova, L. V., Ivanova, S., Peikova, L., & Obreshkova, D. P. (2016) · Folia Medica · doi:10.1515/folmed-2015-0037 · Cited by 34
Løbo, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00014-7 · Cited by 33
Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis
Huang, H., Chuang, A. T.-M., Liao, T., Shao, S., Liu, P. P., Tu, Y., & Lai, E. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.54734 · Cited by 36
Ding, Z., Ma, G., Zhou, B., Cheng, S., Tang, W., Han, Y., Chen, L., Pang, W., Chen, Y., Yang, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101665 · Cited by 35
Kim, K., Svedbom, A., Luo, X., Sutradhar, S., & Kanis, J. A. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2521-4 · Cited by 31
Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?
Ciccarelli, F., Martinis, M. D., & Ginaldi, L. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106125051 · Cited by 31
Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications
Terpos, E., & Dimopoulos, M. A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0974-x · Cited by 31
Hallmer, F., Bjørnland, T., Nicklasson, A., Becktor, J. P., & Andersson, G. (2014) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2014.05.006 · Cited by 31
Kjelgaard-Petersen, C. F., Platt, A., Braddock, M., Jenkins, M. A., Musa, K., Graham, E., Gantzel, T., Slynn, G., Weinblatt, M. E., Karsdal, M. A., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40527 · Cited by 31
Genetic approaches to metabolic bone diseases
Hannan, F. M., Newey, P. J., Whyte, M. P., & Thakker, R. V. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13803 · Cited by 32
Management of comorbidities in haemophilia
Kempton, C. L., Makris, M., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14013 · Cited by 31
Rheumatoid arthritis and bone health
Ashai, S., & Harvey, N. C. (2020) · Clinical Medicine · doi:10.7861/clinmed.20.6.rabh · Cited by 31
Sato, T., Verma, S. K., Khatri, A., Dean, T., Göransson, O., Gardella, T. J., & Wein, M. N. (2020) · JBMR Plus · doi:10.1002/jbm4.10441 · Cited by 29
Therapeutics for enhancement of spinal fusion: A mini review
Zhang, Y., Jiang, Y., Zou, D., Yuan, B., Ke, H. Z., & Li, W. (2021) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2021.11.001 · Cited by 31
Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
Ha, J., Kim, J., Jeong, C., Lim, Y., Kim, M. K., Kwon, H.-S., Song, K., Kang, M. I., & Baek, K. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06388-w · Cited by 31
Single-Cell RNA Sequencing: Unravelling the Bone One Cell at a Time
Chai, R. C. C. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00735-w · Cited by 30
Boots, J. M. M., & Quax, R. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01216-w · Cited by 31
Funck‐Brentano, T., Biver, E., Chopin, F., Bouvard, B., Coiffier, G., Souberbielle, J., Garnero, P., & Roux, C. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.01.005 · Cited by 31
Early, C. R., Stuckey, L. J., & Tischer, S. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3367-8 · Cited by 30
Healing of the bone with anti-fracture drugs
Brandi, M. L. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.801959 · Cited by 31
Hif1α is required for osteoclast activation and bone loss in male osteoporosis
Tando, T., Sato, Y., Miyamoto, K., Morita, M., Kobayashi, T., Funayama, A., Kanaji, A., Wu, H., Watanabe, R., Oike, T., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.033 · Cited by 31
Prevention and treatment of bone fragility in cancer patient
Ottanelli, S. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.116 · Cited by 33
Melatonin and periodontal tissues: Molecular and clinical perspectives
Carpentieri, A. R., López, M. E. P., Aguilar, J., & Solá-Morabito, V. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.003 · Cited by 31
Reginster, J., Hattersley, G., Williams, G. C., Hu, M., Fitzpatrick, L. A., & Lewiecki, E. M. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0450-0 · Cited by 32
Hadaya, D., Gkouveris, I., Soundia, A., Bezouglaia, O., Boyce, R. W., Stolina, M., Dwyer, D., Dry, S., Pirih, F. Q. M., Aghaloo, T. L., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3581 · Cited by 31
Tsourdi, E. A., Makras, P., Rachner, T. D., Pοlyzos, S. A., Rauner, M., Mandanas, S., Hofbauer, L. C., & Anastasilakis, A. D. (2018) · Bone · doi:10.1016/j.bone.2018.10.001 · Cited by 29
Evaluation and Treatment of Osteoporosis
O’Connor, K. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.016 · Cited by 30
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
Metadata
- Authors
- Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., & Christiansen, C.
- Affiliations
- University of California, San Francisco (US)
- Columbia University Irving Medical Center (US)
- University of Sheffield (GB)
- University of Auckland (NZ)
- Inserm (FR)
- Amgen (United States) (US)
- University of Verona (IT)
- Center for Clinical & Basic Research (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-20
- Volume
- 361
- Issue
- 8
- Pages
- 756-765
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160005424
- Cited by
- 3,489
- References
- 39
- Citations by year
- 2026: 187 · 2025: 220 · 2024: 203 · 2023: 164 · 2022: 226 · 2021: 210 · 2020: 223 · 2019: 200 · 2018: 208 · 2017: 195 · 2016: 180 · 2015: 238 · 2014: 168 · 2013: 222 · 2012: 197
- FWCI
- 223.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- denosumab, osteoporosis, postmenopausal women, fracture prevention, RANKL inhibition, vertebral fractures, hip fracture, non-vertebral fractures, bone mineral density, monoclonal antibodies, osteoclasts, bone resorption, adverse events, osteonecrosis of the jaw, hypocalcemia, cancer risk, cardiovascular risk
- MeSH terms
- Denosumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Female, Hip Fractures, Humans, Middle Aged, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Remodeling, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
